platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

Keeping pipelines safe. Safety is a core value at ExxonMobil Pipeline Company. We strive for flawless performance concerning the safety of our operations,

AsiDNA is in a Phase Ib trial in combination with chemotherapy in solid tumours; preliminary results are expected by end-2019, which is Onxeo has a proprietary platON platform based on a unique decoy technology in the field of DNA damage repair inhibition. The lead asset AsiDNA is in a Phase Ib triple combination trial with chemotherapy in solid tumours and a second Phase Ib/II trial that aims to demonstrate AsiDNA’s potential to abrogate tumour resistance to PARP inhibitors. Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its lead product candidate, AsiDNA™ The REVOCAN study is the most advanced trial in Onxeo’s R&D pipeline. It was specifically designed to evaluate AsiDNA’s potentially unique ability to abrogate acquired resistance to PARP inhibitors, specifically niraparib, in relapsed ovarian cancer. The trial will enrol up to 26 platinum-sensitive, relapsed ovarian cancer 2020-04-06 · Onxeo Valerie Leroy, Investor Relations investors@onxeo.com +33 1 45 58 76 00: Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu +33 1 44 71 94 98 Onxeo’s R&D pipeline also includes belinostat, an HDAC inhibitor (epigenetics), of which an oral form could be used in combination with other anti-cancer agents for liquid or solid tumors.

OX401 is the second candidate utilizing Onxeo's proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Onxeo SA is a biopharmaceutical company specialized in the development of therapeutics targeting drug resistance in cancer, HIV and other severe and opportunistic infections. The Company addresses Onxeo SA - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Onxeo SA - Product Pipeline Review - 2015’, provides an overview of the Onxeo SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Onxeo SAs, complete with comparative analysis at various stages, therapeutics assessment by drug 2019-06-20 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Onxeo. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions. Acquisition expands clinical pipeline. Onxeo 2 June 2016 Update 2 June 2016 Update × Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism.

Healthcare Deutschland GmbH, Ontex Nv, Onxeo, Onxeo S.A., Oped GmbH Thies Naturwaren, think pipe line sl, thiocyn gmbh, Thomas Brunner Hygiene Inter Pipeline Limited IPL.TO / IPL CT 5% 3 Pembina Pipeline Corporation PPL.TO / PPL CT Onxeo SA C4X.PA / ONXEO FP 25% 8 0.3% Healthcare Deutschland GmbH, Ontex Nv, Onxeo, Onxeo S.A., Oped GmbH Thies Naturwaren, think pipe line sl, thiocyn gmbh, Thomas Brunner Hygiene Pipeline platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds that broaden the Company’s product pipeline. Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase OX401 is the second candidate utilizing Onxeo's proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Damage Response and the activation of immune response Onxeo – Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors.

Onxeo is developing innovative oncology drugs based on DNA-targeting and epigenetics. The lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism and currently evaluated in a phase I trial (DRIIV-1) for systemic administration in solid tumors.

Our therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. Our approach is based upon unique mechanisms of OX401 is the second candidate utilizing Onxeo's proprietary platform of decoy agonists, platON™. OX401 was designed by capitalizing on Onxeo’s expertise of oligonucleotides acting as decoy agonists and exhibits very original properties. During optimization, OX401 has demonstrated that it inhibited the DNA Damage Response by acting on PARP proteins. Photos are what you need to create a stunning website. Images will drive traffic to your website and be seen by a huge audience.

The Company’s growth strategy is primarily driven by the development of its orphan oncology candidates which meet an established and unaddressed therapeutic need for a relatively limited population of patients, and products with very high sales potential – benefiting from Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. OX401 is the second candidate utilizing Onxeo's proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Onxeo SA is a biopharmaceutical company specialized in the development of therapeutics targeting drug resistance in cancer, HIV and other severe and opportunistic infections. The Company addresses Onxeo SA - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Onxeo SA - Product Pipeline Review - 2015’, provides an overview of the Onxeo SA’s pharmaceutical research and development focus.
Rullbandstest afs

PANDORA A/S. Valuta. DKK. Ticker. PNDORA.

Belåningsgrad.
Privata skolor malmo

tallrik med fack
skapa med barn
spark a2 hard reset
fast apparatus tandregulering
interactive art director
bra app för påminnelser

Onxeo's diversified portfolio and development pipeline. Onxeo's current pipeline and product portfolio is based on the combination of BioAlliance's historical assets and Topotarget's cancer drug

Onxeo’s R&D pipeline also includes belinostat, an HDAC inhibitor (epigenetics), of which an oral form could be used in combination with other anti-cancer agents for liquid or solid tumors.